These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8657531)

  • 1. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.
    Kline MW; Fletcher CV; Federici ME; Harris AT; Evans KD; Rutkiewicz VL; Shearer WT; Dunkle LM
    Pediatrics; 1996 Jun; 97(6 Pt 1):886-90. PubMed ID: 8657531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
    Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.
    Raffi F; Reliquet V; Auger S; Besnier JM; Chennebault JM; Billaud E; Michelet C; Perre P; Lafeuillade A; May T; Billaudel S
    AIDS; 1998 Oct; 12(15):1999-2005. PubMed ID: 9814868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.
    de Mendoza C; Ramos JT; Ciria L; Fortuny C; García FJ; de José MI; Asensi F; Soriano V
    HIV Clin Trials; 2002; 3(1):9-16. PubMed ID: 11819180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
    Kline MW; Dunkle LM; Church JA; Goldsmith JC; Harris AT; Federici ME; Schultze ME; Woods L; Loewen DF; Kaul S
    Pediatrics; 1995 Aug; 96(2 Pt 1):247-52. PubMed ID: 7630678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
    J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug combo safe for HIV-infected children.
    NIAID AIDS Agenda; 1996 Sep; ():7. PubMed ID: 11363927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
    Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
    AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
    García F; Knobel H; Sambeat MA; Arrizabalaga J; Aranda M; Romeu J; Dalmau D; Segura F; Gomez-Sirvent JL; Ferrer E; Cruceta A; Gallart T; Pumarola T; Miró JM; Gatell JM;
    AIDS; 2000 Nov; 14(16):2485-94. PubMed ID: 11101059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
    Kline MW; Calles NR; Simon C; Schwarzwald H
    Pediatr Infect Dis J; 2000 Nov; 19(11):1083-6. PubMed ID: 11099091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.
    Pollard RB; Peterson D; Hardy D; Pottage J; Murphy RL; Gathe J; Beall G; Rutkievicz V; Reynolds L; Cross AP; Dunkle LM
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):39-48. PubMed ID: 10534145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.
    Fletcher CV; Brundage RC; Remmel RP; Page LM; Weller D; Calles NR; Simon C; Kline MW
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1029-34. PubMed ID: 10722507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
    AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
    Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.